Progress with novel pharmacological strategies for gastro-oesophageal reflux disease.
D000818:Animals; D002908:Chronic Disease; D058786:GABA-B Receptor Agonists; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000503:physiopathology; D005765:Gastrointestinal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D018727:Muscarinic Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors; D011964:Receptors, Gastrointestinal Hormone / Q000819:agonists / Q000037:antagonists & inhibitors; D018013:Receptors, Neuropeptide / Q000819:agonists / Q000037:antagonists & inhibitors; D011957:Receptors, Opioid / Q000819:agonists; D017366:Serotonin Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use
D058786:GABA-B Receptor Agonists; D005765:Gastrointestinal Agents; D018727:Muscarinic Antagonists; D011949:Receptors, Cholecystokinin; D011964:Receptors, Gastrointestinal Hormone; D018013:Receptors, Neuropeptide; D011957:Receptors, Opioid; D017366:Serotonin Receptor Agonists; C050802:motilin receptor; D019001:Nitric Oxide Synthase